Sonnet BioTherapeutics is taking the fight directly to cancer using its proprietary FHAB™ technology to empower innovative targeted biologic drugs.
Employees: 1-10
Founded date: 2015
Investors 1
| Date | Name | Website |
| - | Altium Cap... | altiumcap.... |
Mentions in press and media 10
| Date | Title | Description |
| 09.02.2022 | Sonnet BioTherapeutics : Announces Abstract Accepted for Presentation in a Poster Session at the AACR 2022 Annual Meeting | Sonnet BioTherapeutics Announces Abstract Accepted for Presentation in a Poster Session at the AACR 2022 Annual Meeting Download as PDFFebruary 09, 2022 6:30am EST PRINCETON, NJ / ACCESSWIRE / February 9, 2022 / Sonnet BioTherapeutics Holdi... |
| 08.02.2022 | Sonnet BioTherapeutics : Provides Fiscal Year 2022 First Quarter Business and Earnings Update | Sonnet BioTherapeutics Provides Fiscal Year 2022 First Quarter Business and Earnings Update Download as PDFFebruary 08, 2022 7:00am EST SON-1010 and SON-080 on track to initiate clinical studies during the second quarter of 2022 Completed R... |
| 17.12.2021 | Sonnet BioTherapeutics : Provides Fiscal Year 2021 Business and Financial Update | Sonnet BioTherapeutics Provides Fiscal Year 2021 Business and Financial Update Download as PDFDecember 17, 2021 6:30am EST PRINCETON, NJ / ACCESSWIRE / December 17, 2021 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet&qu... |
| 17.12.2021 | Sonnet BioTherapeutics : Annual Report (Form 10-K) | UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2021 Or ☐ TRANSITION... |
| 30.08.2021 | Sonnet BioTherapeutics : Announces Successful Completion of the Discovery Phase for Its Next Preclinical Pipeline Candidate (SON-1410) | Sonnet Announces Successful Completion of the Discovery Phase for Its Next Preclinical Pipeline Candidate (SON-1410) Download as PDFAugust 30, 2021 4:01pm EDT SON-1410 (IL18-FHAB-IL12), a bispecific combination of Interleukins 18 and 12, wa... |
| 20.08.2021 | Sonnet BioTherapeutics : Announces Pricing of $30 Million Underwritten Public Offering | Sonnet BioTherapeutics Announces Pricing of $30 Million Underwritten Public Offering Download as PDFAugust 19, 2021 9:35pm EDT PRINCETON, NJ / ACCESSWIRE / August 19, 2021 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ('Sonnet' or t... |
| 14.06.2021 | SONNET BIOTHERAPEUTICS HOLDINGS, INC. Sonnet BioTherapeutics : Announces Change in Date of Annual Meeting | Sonnet BioTherapeutics Announces Change in Date of Annual Meeting Download as PDFJune 14, 2021 7:45am EDT Annual Meeting to be Held Thursday July 15, 2021. PRINCETON, NJ/ACCESSWIRE/June 14, 2021/ Sonnet BioTherapeutics Holdings, Inc., (NASD... |
| 08.06.2021 | SONNET BIOTHERAPEUTICS HOLDINGS, INC. Sonnet BioTherapeutics : Announces Issuance of U.S. Patent for Platform Technology | Sonnet BioTherapeutics Announces Issuance of U.S. Patent for Platform Technology Download as PDFJune 08, 2021 4:30pm EDT U.S. Patent and Trademark Office issued US Patent No. 11,028,166 for the Company's Fully Human Albumin Binding Domain F... |
| 10.05.2021 | Sonnet BioTherapeutics : Completes Successful GLP Repeat Dose Toxicology Study of IL12-FHAB (SON-1010) in Non-Human Primates (NHP) | Sonnet BioTherapeutics Completes Successful GLP Repeat Dose Toxicology Study of IL12-FHAB (SON-1010) in Non-Human Primates (NHP) Download as PDFMay 10, 2021 6:30am EDT The No Observed Adverse Event Level (NOAEL) following repeated administr... |
| 29.12.2019 | Wrapping Up CLT’s 2019: Q4 Deals in the Queen City | An exciting Q4 in the Carolinas has left many startups looking forward to a successful 2020. We thought the best way to ring in the new year would be to look back at the most noteworthy fundings, deals, exits, mergers, and acquisitions duri... |